Sarilumab

BNF:

Not listed

Status:

Red

Decision Date:

December 2017

Comments

RED^1,2,3: NICE TA485 - Sarilumab for moderate to severe rheumatoid arthritis. (Decision date - December 2017)

CCG commissioned drug.

Red Drug Classifications

• 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
• 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
• 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)

search again